The changing role of radium-223 in metastatic castrate-resistant prostate cancer: has the EMA missed the mark with revising the label?
- 1 September 2019
- journal article
- review article
- Published by Edizioni Minerva Medica in The Quarterly Journal of Nuclear Medicine and Molecular Imaging
- Vol. 63 (2) , 170-182
Abstract
Radium-223 (Ra-223) is a life-prolonging treatment in symptomatic men with metastatic castrate-resistant prostate cancer (mCRPC) and bone metastases, but no visceral disease, regardless of prior treatment with docetaxel. Together with four other drugs (i.e. abiraterone, cabazitaxel, docetaxel, enzalutamide), it has been available for clinical use since 2013 and has been shown to also provide benefits in quality-of-life and societal benefits. However, in 2018 the European Medicines Agency ruled to restrict the use of radium-223 to a more advanced disease setting after at least two lines of one or the other life-prolonging agent. This decision was triggered by the results of a safety interim analysis of ERA-223, a trial investigating the combination of Ra-223 and abiraterone versus abiraterone alone in patients without prior chemotherapy (with the exception of adjuvant treatment) with asymptomatic bone predominant mCRPC. That safety analysis showed an early increased risk of fracture and deaths with the combination treatment. This review critically appraises the available and emerging data with Ra-223 treatment in an attempt to assess the appropriateness of the revised label of radium-223.Keywords
This publication has 67 references indexed in Scilit:
- ESMO-Magnitude of Clinical Benefit Scale version 1.1Annals of Oncology, 2017
- Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trialEuropean Journal of Cancer, 2017
- Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA studyAnnals of Oncology, 2016
- The Project Data Sphere Initiative: Accelerating Cancer Research by Sharing DataThe Oncologist, 2015
- Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trialThe Lancet Oncology, 2014
- Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trialThe Lancet Oncology, 2014
- Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate CancerJournal of Clinical Oncology, 2014
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2013
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- On the role of finite mixture models in survival analysisStatistical Methods in Medical Research, 1994